Genome Editing by CRISPR | NMI TT Pharmaservices

home contact company.overview news sitemap print privacy

Custom Cell Services


NMI-TT Contact Person

Dr. Richard Griesbach

+49 7121 51530 74

Download Flyer

Genome Editing by CRISPR/Cas9

Based on our long-standing expertise in generating customised cell lines, we are now also employing the CRISPR/Cas9 genome editing approach.

Full freedom to operate (FTO) is ensured through a set of license agreements (please see our agreement with ERS Genomics).

    Our offerings:
  • Introduction of specifically site-directed double stand breaks applying the CRISPR/Cas9 technology
  • Generation of target-defective / knockout cell lines
  • Larger deletions by two double strand breaks
  • Insertion of specific mutations or extensions into the DNA locus with ectopic repair templates
  • Generation of synthetic human hiPSC disease models
  • CRISPR editing of primary T cells
The CRISPR/Cas9 technology can also be used for target validation, analogous to RNAi mediated target silencing.


Linked in profile

NMI TT is a subsidiary of NMI